Aktis Oncology, Inc. (AKTS) insider trading
Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 19, 2026.
- Filings shown
- 9
- Open-market buys
- 2
- Open-market sells
- 11
- Buys, 10b5-1 box not checked
- 2 of 2
Counts cover the 9 most recent Form 4 filings Tradune holds for AKTS (filed Jan 14 – Nov 19, 2026); the score below covers only the trailing 90 days (0 buys, 2 sells). SEC EDGAR Form 4 filings for AKTS last checked Nov 21, 2026, 09:00 UTC; the latest AKTS filing Tradune holds was filed Nov 19, 2026. This is not guaranteed to be the complete record — see AKTS's full Form 4 filing history on SEC EDGAR.
Open-market activity, last 90 days
Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for AKTS filed Sep 24 – Nov 19, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.
2 open-market sales by Rule 10b5-1 checkbox
- On filings with the 10b5-1 box checked
- 2 sales· 12,500 sh
- checkbox disclosed
- On filings with the box not checked
- 0 sales· 0 sh
- not proof that no plan exists
- Not comparable
- 0 sales· 0 sh
- filed before Apr 1, 2023, or no checkbox value in the filing data
Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.
| Insider | Buys | Sells | Shares bought | Shares sold | Value |
|---|---|---|---|---|---|
| Akos CzibereChief Medical Officer | 0 | 2 | — | 12,500 | −$258,621 |
Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.
Insider-activity score
0/ 100
Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →
Get alerted when insiders buy the stocks you own
Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.
Free for everyone right now · no card · nothing to buy
How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).
Insider Buying at AKTS
Insiders reported 2 open-market purchases of AKTS between Jan 14, 2026 and Nov 19, 2026, across 2 distinct buyers. The most recent purchase was reported by Ansbert Gadicke (10% owner) on Jan 12, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Recent Form 4 filings
Source: SEC EDGAR Form 4 · transaction codes explained
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise Stock Option (Right to Buy) | 55,035 | — | — | — | Nov 18, 2026 |
| Option exercise | 55,035 | $1.90 | 199,603 | +38% | Nov 18, 2026 |
† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise Stock Option (Right to Buy) | 12,500 | — | — | — | Sep 23, 2026 |
| Open-market sale 10b5-1 box checked | 7,401 | $21.03 | 0 | −100% | Sep 23, 2026 |
| Open-market sale 10b5-1 box checked | 5,099 | $20.19 | 7,401 | −41% | Sep 23, 2026 |
| Option exercise | 12,500 | $4.95 | 12,500 | — | Sep 23, 2026 |
“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 3,506 | $24.56 | 1,350 | −72% | Jul 20, 2026 |
| Open-market sale 10b5-1 box not checked | 1,350 | $24.56 | 0 | −100% | Jul 20, 2026 |
| Option exercise Stock Option (Right to Buy) | 3,506 | — | — | — | Jul 20, 2026 |
| Option exercise Stock Option (Right to Buy) | 1,350 | — | — | — | Jul 20, 2026 |
| Option exercise | 3,506 | $0.08 | 3,506 | — | Jul 20, 2026 |
| Option exercise | 1,350 | $1.91 | 4,856 | +39% | Jul 20, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise Stock Option (Right to Buy) | 3,065 | — | — | — | Jul 17, 2026 |
| Open-market sale 10b5-1 box not checked | 3,065 | $25.21 | 0 | −100% | Jul 17, 2026 |
| Option exercise | 3,065 | $0.08 | 3,065 | — | Jul 17, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise | 50,000 | $3.66 | 50,000 | — | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 15,800 | $27.13 | 34,200 | −32% | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 4,200 | $28.75 | 0 | −100% | Jul 8, 2026 |
| Option exercise Stock Option (Right to Buy) | 50,000 | — | — | — | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 30,000 | $27.94 | 4,200 | −88% | Jul 8, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise Stock Option (Right to Buy) | 50,000 | — | — | — | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 14,800 | $27.13 | 35,200 | −30% | Jul 8, 2026 |
| Option exercise | 50,000 | $4.95 | 50,000 | — | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 30,829 | $27.95 | 4,371 | −88% | Jul 8, 2026 |
| Open-market sale 10b5-1 box not checked | 4,371 | $28.71 | 0 | −100% | Jul 8, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 37,866 | — | — | — | Apr 15, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Conversion of derivative Series Seed Redeemable Convertible Preferred Stock | 2,272,727 | — | — | — | Jan 12, 2026 |
| Conversion of derivative Series B Redeemable Convertible Preferred Stock | 2,727,273 | — | — | — | Jan 12, 2026 |
| Conversion of derivative Series A Redeemable Convertible Preferred Stock | 10,227,273 | — | — | — | Jan 12, 2026 |
| Conversion of derivative | 2,688,270 | — | 3,285,661 (indirect) | +450% | Jan 12, 2026 |
| Open-market purchase 10b5-1 box not checked | 232,870 | $18.00 | 4,235,403 (indirect) | +5.8% | Jan 12, 2026 |
| Conversion of derivative | 597,391 | — | 597,391 (indirect) | — | Jan 12, 2026 |
| Conversion of derivative | 716,872 | — | 4,002,533 (indirect) | +22% | Jan 12, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Conversion of derivative | 1,314,262 | — | 1,655,971 (indirect) | +385% | Jan 12, 2026 |
| Conversion of derivative | 5,914,197 | — | 7,570,168 (indirect) | +357% | Jan 12, 2026 |
| Conversion of derivative | 1,577,119 | — | 9,147,287 (indirect) | +21% | Jan 12, 2026 |
| Open-market purchase 10b5-1 box not checked | 1,112,777 | $18.00 | 10,260,064 (indirect) | +12% | Jan 12, 2026 |
| Conversion of derivative Series Seed Redeemable Convertible Preferred Stock | 5,000,000 | — | — | — | Jan 12, 2026 |
| Conversion of derivative Series A Redeemable Convertible Preferred Stock | 22,500,000 | — | — | — | Jan 12, 2026 |
| Conversion of derivative Series B Redeemable Convertible Preferred Stock | 6,000,000 | — | — | — | Jan 12, 2026 |
Insider filings reported around the same time
Other companies whose most recent Form 4 was filed closest to AKTS's (Nov 19, 2026).
Frequently asked about AKTS insider activity
How many insiders bought AKTS stock in these Form 4 filings?
2 distinct insiders at Aktis Oncology, Inc. reported 2 open-market purchases (Form 4 code P) of AKTS shares between Jan 14, 2026 and Nov 19, 2026, the most recent filed by Ansbert Gadicke (10% owner) on Jan 12, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Who filed the most recent Form 4 for AKTS?
The most recent Form 4 on this page was filed by Paul L. Feldman (Chief Scientific Officer) on Nov 19, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.
What was the largest open-market AKTS insider purchase shown?
The largest open-market purchase among the filings shown was 1,112,777 AKTS shares at $18.00 (about $20,029,986) by Ansbert Gadicke (10% owner) on Jan 12, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.
Do the recent AKTS insider purchases have the Form 4 10b5-1 box checked?
No. All 2 AKTS open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Ansbert Gadicke (10% owner) on Jan 12, 2026, 1,112,777 shares.
New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.
Get insider alerts for AKTS — and your whole portfolio
Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy
This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.
Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.